FBR Capital Remains Buyers of CVS Health (CVS) Following 'Solid' Quarter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
CVS, Express Scripts 2017 Formulary Exclusion Lists Make Waves
August 2, 2016 11:56 AM EDTOn Monday, CVS Health (NYSE: CVS) released its 2017 Standard Formulary Exclusion List and Express Scripts (NASDAQ: ESRX) released its 2017 National Preferred Formulary exclusion list.
Below is a summary of analyst commentary around the list changes:
CVS 2017 Standard Formulary Exclusion List:
Barclays analyst Eric Percher said most notably, CVS signaled aggressively on biosimilars, replacing Neupogen with Zarxio (limited impact under the pharmacy benefit) and Lantus with Basaglar for 2017 (significant impact under the pharmacy benefit)
Percher noted a therapeutics focus on Oncology,... More
CVS Health (CVS) to Exclude Sanofi's (SNY) Lantus in 2017 from Main Covered Drug List - Bloomberg
August 2, 2016 9:29 AM EDTCVS Health (NYSE: CVS) to Exclude Sanofi's (NYSE: SNY) Lantus in 2017 from Main Covered Drug List - Bloomberg
... MoreCVS Health (CVS) to Exclude Medivation's (MDVN) Xtandi in 2017 Main Formulary - Bloomberg
August 2, 2016 9:10 AM EDTCVS Health (NYSE: CVS) to Exclude Medivation's (Nasdaq: MDVN) Xtandi in 2017 Main Formulary - Bloomberg
... MoreCVS Health (CVS) Tops Q2 EPS by 2c; Boosts FY16 EPS Outlook
August 2, 2016 6:56 AM EDTCVS Health (NYSE: CVS) reported Q2 EPS of $1.32, $0.02 better than the analyst estimate of $1.30. Revenue for the quarter came in at $43.7 billion versus the consensus estimate of $44.28 billion.
Same store sales increased 2.1% versus the second quarter of 2015. Pharmacy same store sales rose 3.9% and... More
